1-Year Kidney Transplant Outcomes Superior with Pressure-Driven Machine Perfusion

A team from Warsaw Medical University, Poland, has reported results from a prospective, randomized, trial comparing Organ Recovery System’s LifePort®, a pressure driven (PD) device, with Waters Medical Systems’ RM3, a flow driven (FD) device.1 This is the first time the two systems have been compared in patients receiving deceased donor kidneys. The aim of the study was to evaluate any potential impact on kidney transplant outcome between the two systems.

A total of 50 kidneys were retrieved from 25 deceased donors, of which 24 were from 12 ECD. Of the 50 recipients, 25 received a PD-perfused kidney and 25 received a FD-perfused kidney. There were no differences seen in kidney weight before or after cold ischemia time (mean time was 28 hours for both groups). Although not significant, renal flow was higher in FD kidneys; however, renal resistance was significantly lower in PD kidneys from the first hour until the end of perfusion. Biomarker analysis found no differences in mean activation of TNFα, NGAL or KIM-1 in the perfusion solutions, although caspase-3 was significantly higher in the fourth hour of perfusion in FD kidneys. No difference was seen in delayed graft function (DGF) between the two cohorts (32%). Interestingly, in patients with DGF, the mean number of post-transplant dialysis sessions was significantly lower in PD patients compared with the FD group (2.65 versus 4.66; p=0.004). While overall 1-year graft survival was 88% (44/50), in PD patients it was 96% (24/25) and in FD patients 80% (20/25; p=0.07). In ECD kidneys, 1-year graft survival was 92% (11/12) in the PD group and 66% (8/12) in the FD group (p=0.09). Also noteworthy are the significantly lower mean pressures registered on the PD device, which data have already shown to be associated with lower activation of von Willebrand factor, a marker of endothelial injury.2 The group believes that these data warrant further investigation in a larger study in order to improve the power of the results.

1. Wszola M et al. One-year results of a prospective, randomized trial comparing two machine perfusion devices used for kidney preservation. Transpl Int 2013;26(11):1088–96.
2. Maathuis MH et al. Improved kidney graft function after preservation using a novel hypothermic machine perfusion device. Ann Surg 2007;246:982–91.

Tagged In:

Clinical, HMP, Kidney

The Latest

Check out the most recent posts

Fox19—UC Health Performs First Cold Pump Liver Transplant

In this article from FOX19 NOW, meet the first liver transplant patient to receive a cold pump liver which was pumped on a LifePort® Liver Transporter during its clinical trial, PILOT™. PILOT (Perfusion to Improve Liver Outcomes in Transplantation) is a...

ABC12 News—Organ Transplant Goes Hi-tech

In this article, Intermountain Healthcare takes part in the PILOT™ clinical trial of the LifePort® Liver Transporter. PILOT (Perfusion to Improve Liver Outcomes in Transplantation) is a prospective randomized multi-center oxygenated hypothermic machine...

KSLTV—Doctors Testing New Liver Transplant Transport System

In this article, KSLTV of Salt Lake City reports on Intermountain Healthcare’s participation in the LifePort Liver Transporter clinical trial. “We’re keeping that liver working in a somewhat normal, physiologic state during the time that it’s out of the donor’s body...